

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-3. (Cancelled)

4. (Currently Amended) A method for preventing, treating or delaying neoplasm in a mammal, which method comprises administering to a mammal, to which such prevention, treatment or delay is needed or desirable, an effective amount of an ErbB-3 protein, ~~or a functional fragment thereof~~, whereby an immune response is generated against said neoplasm is prevented, treated or delayed, wherein the ErbB-3 protein comprises:

- (a) the amino acid sequence set forth in SEQ ID NO:13; or
- (b) ~~at least~~ amino acid residues 24-81 of the amino acid sequence set forth in SEQ ID NO:14; or
- (c) ~~at least~~ amino acid residues 2-139 of the amino acid sequence set forth in SEQ ID NO:16; ~~or~~
- (d) ~~the amino acid sequence set forth in SEQ ID NO:2; or~~
- (e) ~~the amino acid sequence set forth in SEQ ID NO:3,~~
wherein the ErbB-3 protein is not the extracellular domain of ErbB-3.

5. (Cancelled)

6. (Previously Presented) The method of claim 4, further comprising administering an immune response potentiator to the mammal.

7. (Cancelled)

8. (Cancelled)

9. (Currently Amended) The method of claim 4, wherein the ErbB-3 protein, ~~or the functional fragment thereof~~, is co-administered with a pharmaceutically acceptable carrier or excipient.

10. (Currently Amended) The method of claim 4, wherein the ErbB-3 protein, or the functional fragment thereof, is co-administered with an anti-neoplasm agent.

11. (Previously Presented) The method of claim 10, wherein the anti-neoplasm agent is selected from the group consisting of an anti-angiogenic agent, an alkylating agent, an antimetabolite, a natural product, a platinum coordination complex, an anthracenedione, a substituted urea, a methylhydrazine derivative, an adrenocortical suppressant, a hormone, an antagonist, an oncogene inhibitor, a tumor suppressor gene or protein, an anti-oncogene antibody and an anti-oncogene antisense oligonucleotide.

12. (Previously Presented) The method of claim 4, wherein the neoplasm to be prevented, treated or delayed is selected from the group consisting of adrenal gland, anus, auditory nerve, bile ducts, bladder, bone, brain, breast, bruccal, central nervous system, cervix, colon, ear, endometrium, esophagus, eye, eyelids, fallopian tube, gastrointestinal tract, head and neck, heart, kidney, larynx, liver, lung, mandible, mandibular condyle, maxilla, mouth, nasopharynx, nose, oral cavity, ovary, pancreas, parotid gland, penis, pinna, pituitary, prostate gland, rectum, retina, salivary glands, skin, small intestine, spinal cord, stomach, testes, thyroid, tonsil, urethra, uterus, vagina, vestibulocochlear nerve and vulva neoplasm.

13. (Previously Presented) The method of claim 4, wherein the neoplasm to be prevented, treated or delayed is selected from the group consisting of breast, ovary, stomach, prostate, colon and lung cancer.

14. (Previously Presented) The method of claim 4, wherein the neoplasm to be prevented, treated or delayed is breast cancer.

15-43. (Cancelled)

44. (Previously Presented) The method of claim 4, wherein the mammal is a human.

45. (Previously Presented) The method of claim 4, wherein the administering is by intracavernous injection, subcutaneous injection, intravenous injection, intramuscular injection, intradermal injection, oral administration or topical administration.